ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CAMP vs VNDA // EV/EBITDA & P/E VALUATION

CAMP4 Therapeutics Corporation (NASDAQ) VS. Vanda Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: CAMP 2 — VNDA 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAMP VS. VNDA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CAMP VNDA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -12.19% — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% 8.70% +171.30 CAMP /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 58.9 26.7 +32.24 CAMP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $244.7M $244.9M -$136.4K VNDA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CAMP REV VNDA REV CAMP GROSS % VNDA GROSS % CAMP FCF VNDA FCF
FY 2025 $3.5M $216.1M — — -$29.8M -$110.4M
FY 2024 $652.0K $198.8M — — -$46.0M -$16.2M
FY 2023 $350.0K $192.6M — — -$44.2M $12.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAMP // BETA —
VNDA // BETA —